Dr. Immergluck is a pediatrician, a pediatric infectious disease specialist, and population health service researcher, who has spent over 25 years studying the impact of antibiotic resistant infections and vaccine preventable conditions in children. At UCM, she will focus on clinical vaccine and infectious disease related therapeutic trials and public health matters related to the prevention of infectious diseases among medically underserved populations including how SDOH factors influence the spread of infections.
She received her B.A. degree from Northwestern University in Evanston, Illinois and received her medical degree from The Ohio State University College of Medicine in 1990. Once completing her residency in Pediatrics at the University of Chicago Children’s Hospital, she also completed a fellowship in Pediatric Infectious Diseases at the University of Chicago. She was a recipient of the Pediatric Scientist Development Award in 1994, where she developed a primary neuronal model to study requirements for herpes simplex entry, working with Dr. Nancy B. Schwartz.
Dr. Immergluck served as an Assistant Professor of Pediatrics at the University of Illinois at Chicago from 1996-2002 and subsequently as Associate Professor of Pediatrics at Michigan State University serving as Director of the Pediatric Infectious Diseases Program at DeVos Children’s Hospital from 2002-2005. Most recently, Dr. Immergluck served as a Professor and Physician Scientist at Morehouse School of Medicine, Director of the Pediatric Clinical Translational Research Unit and the Vaccine Trial Unit at the Clinical Research Center, and site Principal Investigator for its participation in the U.S. COVID-19 Prevention Network, including COVID-19 Vaccine Clinical Trials. Concurrently, she served as an adjunct Associate Professor at Emory University's Rollins School of Public Health and Research Director for the Pediatric Emergency Medicine Associates group in Atlanta, Georgia. Over the last decade, she has addressed how children’s socio ecological conditions impact their health and wellness with emphasis on conditions and diseases which disproportionately affect children of color, e.g., asthma, sickle cell. In 2012, she received her Master of Science in Clinical Research and in 2015, working with her mentors (Dr. George S. Rust and Dr. Lance A. Waller) she was awarded a five-year K08 grant from the Agency for Healthcare Research and Quality to apply geospatial statistical modeling to understand the impact of socio environmental factors which affect the transmission and spread of community associated antibiotic resistance infections in otherwise healthy children.
Dr. Immergluck serves on the American Academy of Pediatrics, Executive Board for the Section on Infectious Diseases, and is committed to increase the diversity in pipeline programs for the next generation of biomedical scientists and physician scientists.
Morehouse School of Medicine
Atlanta
M.S. - Clinical Research
2013
University of Chicago
Chicago
- Fellow, Pediatric Infectious Diseases
1996
University of Chicago
Chicago
- Fellow, Pediatric Scientist Development Program
1996
University of Chicago
Chicago
- Resident Physician, Pediatrics
1993
The Ohio State University
Columbus
M.D. - Medicine
1990
Northwestern University
Evanston
B.A. - Biochemistry/Molecular and Cell Biology
1986
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2024 Sep 26.
PMID: 39325506
Describing the Heterogeneity of Clinical Utilization of Congenital Syphilis Diagnostic Modalities Among Major United States Tertiary Children's Hospitals, 2017-2022.
Describing the Heterogeneity of Clinical Utilization of Congenital Syphilis Diagnostic Modalities Among Major United States Tertiary Children's Hospitals, 2017-2022. Sex Transm Dis. 2024 Dec 01; 51(12):780-783.
PMID: 39046167
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. J Infect Dis. 2023 12 20; 228(12):1662-1666.
PMID: 37561027
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021. Open Forum Infect Dis. 2023 Nov; 10(11):ofad511.
PMID: 38023544
Molecular Epidemiologic and Geo-Spatial Characterization of Staphylococcus aureus Cultured from Skin and Soft Tissue Infections from United States-Born and Immigrant Patients Living in New York City.
Molecular Epidemiologic and Geo-Spatial Characterization of Staphylococcus aureus Cultured from Skin and Soft Tissue Infections from United States-Born and Immigrant Patients Living in New York City. Antibiotics (Basel). 2023 Oct 14; 12(10).
PMID: 37887242
Machine learning to predict risk for community-onset Staphylococcus aureus infections in children living in southeastern United States.
Machine learning to predict risk for community-onset Staphylococcus aureus infections in children living in southeastern United States. PLoS One. 2023; 18(9):e0290375.
PMID: 37656705
Measles Update in an Era of Vaccine Hesitancy and Global Pandemic.
Measles Update in an Era of Vaccine Hesitancy and Global Pandemic. Pediatr Rev. 2023 09 01; 44(9):529-532.
PMID: 37653130
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023 09; 29(9):2334-2346.
PMID: 37640860
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
PMID: 37036397
Population-Level Disparities in Exposure to COVID-19 Mitigation Policies, April 2020-April 2021.
Population-Level Disparities in Exposure to COVID-19 Mitigation Policies, April 2020-April 2021. J Public Health Manag Pract. 2023 Nov-Dec 01; 29(6):874-881.
PMID: 37498523